CMS-D001

Primary objective: To evaluate the safety and tolerability of single or multiple oral doses of CMS-D001; Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of single or multiple oral doses of CMS-D001, 2) To evaluate the pharmacodynamic (PD) characteristics of single or multiple oral doses of CMS-D001; Other objectives: 1) To investigate the metabolites/characteristics in plasma, 2) To evaluate the effects of oral CMS-D001 on the cardiac QT interval.

To evaluate the preliminary efficacy, safety, and PK characteristics of CMS-D001 in patients with moderate to severe plaque psoriasis.